EGFR and glioblastoma: Additionally, Whittle et al. described a phase I clinical trial on patients affected by recurrent GBM treated with weekly administration of novel nano cellular compounds loaded with a chemotherapeutic agent and functionalized with anti-EGFR antibodies, demonstrating no dose-limiting toxicity in fourteen patients [44].